Selecting patients with HER2-low breast cancer: Getting out of the tangle-Reference-Cited by-同舟云学术

Selecting patients with HER2-low breast cancer: Getting out of the tangle

Published:2022-11 Issue: Volume:175 Page:187-192
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Baez-Navarro Ximena,Salgado Roberto,Denkert Carsten,Lennerz Jochen K.,Penault-Llorca Frédérique,Viale Giuseppe,Bartlett John M.S.,van Deurzen Carolien H.M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials;Lancet Oncol,2021

2. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American pathologists clinical practice guideline focused update;Wolff;Arch Pathol Lab Med,2018

3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;Wolff;J Clin Oncol,2007

4. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

5. HER2-Low breast cancers;Zhang;Am J Clin Pathol,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay;Modern Pathology;2024-09

2. Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer;Clinical and Translational Oncology;2024-08-22

3. Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray;PLOS ONE;2024-05-15

4. HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study;Pathology;2024-04

5. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer;European Journal of Cancer;2024-04